Glutamine metabolism is one of the hallmarks of ovarian cancer and is known to stimulate the mTOR/MAPK and STAT3 signaling pathways, and inhibition of glutamine metabolism has been shown to provide therapeutic benefits [50,51]. This evidence concerns the gene STAT3 and ovarian cancer.